1. Home
  2. AKBA vs IIIV Comparison

AKBA vs IIIV Comparison

Compare AKBA & IIIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$1.42

Market Cap

729.1M

Sector

Health Care

ML Signal

HOLD

Logo i3 Verticals Inc.

IIIV

i3 Verticals Inc.

HOLD

Current Price

$21.56

Market Cap

642.1M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
AKBA
IIIV
Founded
2007
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
729.1M
642.1M
IPO Year
2014
2018

Fundamental Metrics

Financial Performance
Metric
AKBA
IIIV
Price
$1.42
$21.56
Analyst Decision
Strong Buy
Buy
Analyst Count
6
6
Target Price
$5.92
$33.33
AVG Volume (30 Days)
3.1M
422.3K
Earning Date
03-12-2026
02-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.51
Revenue
$225,071,000.00
$213,608,000.00
Revenue This Year
$52.41
$8.32
Revenue Next Year
$21.57
$7.26
P/E Ratio
N/A
$41.29
Revenue Growth
32.49
13.38
52 Week Low
$1.30
$19.89
52 Week High
$4.08
$33.97

Technical Indicators

Market Signals
Indicator
AKBA
IIIV
Relative Strength Index (RSI) 46.10 37.33
Support Level $1.35 $21.52
Resistance Level $1.44 $23.00
Average True Range (ATR) 0.08 1.29
MACD 0.01 -0.23
Stochastic Oscillator 42.50 31.45

Price Performance

Historical Comparison
AKBA
IIIV

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

About IIIV i3 Verticals Inc.

i3 Verticals Inc provides mission-critical enterprise software solutions to public sector entities. These comprehensive cloud-native solutions address a broad range of government functions, including courts and public safety, public administration, utilities, transportation and schools. The company generates the majority of revenue from software and related services, including the sale of subscriptions, recurring services, ongoing support, licenses, and installation and implementation services specific to software.

Share on Social Networks: